ClinicalTrials.gg
Sign In
CompletedNCT02516553Updated Apr 15, 2024Results posted

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

A Phase 1 interventional study of BI 894999 in Neoplasms and NUT Carcinoma, sponsored by Boehringer Ingelheim. Completed at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful. In some countries, adolescents who are at least 15 years old and who are diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare and aggressive form of cancer.

The purpose of this study is to find out the highest dose of BI 894999 that people can tolerate.

BI 894999 is tested for the first time in humans. Participants take tablets once daily. The study also tests whether participants can tolerate BI 894999 better when taken continuously or with breaks in between.

Participants can stay in the study as long as they benefit from the treatment and can tolerate it.

The doctors also regularly check the general health of the participants.

02

Conditions studied

  • Neoplasms
  • NUT Carcinoma

Browse trials for

Keywords

  • NUT midline carcinoma
03

In context

Neoplasms

9,616 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's enrollment of 174 is above the median of 50 across 7,429 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,297 studies on the registry; 56 are open to participants now.

Of its 166 completed or terminated interventional studies of FDA-regulated products, 121 (73%) have results posted.

Browse Boehringer Ingelheim studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all patients

  • Age 18 years or older at the time of signature of the informed consent.
  • Life expectancy of at least 12 weeks after the start of the treatment according to the investigator's judgement
  • Male or female patients. Women of childbearing potential* must be ready and able to use highly effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. For women of childbearing potential using a contraceptive pill, an additional barrier method is necessary due to the potential CYP3A4 inducing effect of BI894999. Male patients having a partner of childbearing potential must use condoms and ensure their partner is using a highly effective method of birth control as described above, during the trial and for at least three months after the end of the trial * Any female who has experienced menarche and does not meet the criteria for "women not of childbearing potential" as described below.

Women not of childbearing potential are defined as: women who are postmenopausal (12 months with no menses without an alternative medical cause) or who are permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy).

- Written informed consent consistent with ICH-GCP and local legislation

For patients with solid tumours

  • Patients with a histologically or cytologically confirmed diagnosis of an advanced unresectable and/or metastatic, malignant solid tumour, who have failed conventional treatment or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies
  • Age ≥ legal age to be adult for the given country at the time of signature of the informed consent. For NC patients, age 15 years or older at the time of signature of the informed consent ( in Germany and South Korea, only legally adult patients may be included
  • Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 or 1 at the time of screening. A score of 2 is allowed for NUT carcinoma patients
  • Recovery of therapy-related toxicities from previous chemotherapy, tyrosine kinase inhibitors, hormone therapy, immunotherapy, antibodies, vaccine therapy, or radiotherapy to CTCAE ≤ grade 1 (with the exception of alopecia, peripheral sensory neuropathy grade 2)
  • Life expectancy of at least 12 weeks after the start of the treatment according to the investigator's judgement
  • Male or female patients. Women of childbearing potential* must be ready and able to use highly effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. For women of childbearing potential using a contraceptive pill, an additional barrier method is necessary due to the potential CYP3A4 inducing effect of BI894999. Male patients having a partner of childbearing potential must use condoms and ensure their partner is using a highly effective method of birth control as described above, during the trial and for at least three months after the end of the trial treatment
  • Written informed consent consistent with ICH-GCP and local legislation. For adolescent NC patients aged 15 years to \< legal adult age, written assent of the patient and written informed consent of the parents (both or one according to national regulation) or legal guardian of the adolescent

  • Written informed consent for tumour biopsies in the escalation phase Ia

    • Optional for those patients until extension of the MTD cohort,
    • Optional for the patients in the extension of MTD cohort at the same time points as described below for the expansion phase. For these patients in the extension of the MTD cohort, if they have an accessible lesion for biopsy, they will be offered optional consent for tumour biopsies
  • In addition, all patients included in the expansion Phase Ib must:

  • Have been diagnosed with one of the four types of tumours selected:

    • small cell lung cancer (SCLC)
    • metastatic castrate resistant prostate cancer (mCRPC)
    • colorectal cancer (CRC)
    • NUT carcinoma (NC) (for which the "midline" origin is not a prerequisite)

  • Have failed conventional treatments or who are not amenable to standard therapies (per criterion 1) that specifically include for:

    • SCLC: a platinum-based therapy (previous treatment with topotecan is not mandatory)
    • mCRPC: a hormonal agent (abiraterone, enzalutamide, or apalutamide) and a taxane (docetaxel or cabazitaxel)
    • CRC: fluoropyrimidine, oxaliplatin and irinotecan, bevacizumab for patients eligible to this treatment and an anti-epidermal growth factor receptor (EGFR) in RAS (Rat Sarcoma Virus) wild type metastatic CRC.
  • Have measurable disease (radiated lesions and lesions used for biopsy do not qualify as target lesions), according to RECIST 1.1 (R09-0262) (for NC patients only nonmeasurable disease is acceptable); or according to PCWG3 (R17-3377) for the mCRPC cohort (see point 5 of inclusion criteria below, specific to mCRPC patients)
  • Have progressive disease within the last 6 months, according to RECIST 1.1 (R09-0262) or according to PCWG3 (R17-3377) for the mCRPC cohort (see point 5 of inclusion criteria below, specific to mCRPC patients). NC patients do not need to show progression per RECIST 1.1 (for example, if newly diagnosed).
  • Have a tumour lesion accessible for biopsies (pre- and at steady state under treatment in Cycle 1, ideally from the same anatomic lesion) (except for mCRPC patients having only bone metastases or for patients with therapeutic INR because of treatment with a vitamin K antagonist or a novel oral anticoagulant. Biopsies are optional for NC patients
  • Give written informed consent for two tumour biopsies, one at screening and one after start of treatment, between Day 8 and Day 11 of Cycle 1 (or between day 3 and day 8 if the day of biopsy in Cycle 1 needs to be moved as explained in Section 3.1) (when applicable)
  • In addition, all patients in the mCRPC expansion cohort of Phase Ib must have:
  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • Radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by bone scan, CT scan, or MRI within 28 days before the start of study treatment.
  • PSA ≥ 5 ng/mL (if no measurable disease by RECIST 1.1)
  • Prior surgical or chemical castration with a serum testosterone of \<50 ng/dL (\< 1.7 nmol/L) by luteinizing hormone releasing level hormone (LHRH) agonist or antagonist, or by abiraterone or by enzalutamide or apalutamide. If the actual method of castration is LHRH agonist or antagonist, the patient must be willing to continue the use of LHRH agonist or antagonist during protocol treatment.

  • Progressive disease defined as at least one of the following:

    • Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1
    • Bone scan progression: at least two new lesions on bone scan plus a rising PSA as described in point c below
    • Increasing PSA level: at least two consecutive rising PSA values over a reference value (PSA no.1) taken at least 1 week apart. A third PSA (PSA no. 3) is required to be > than PSA no. 2; if not, a fourth PSA (PSA no. 4) is required to be > to PSA no. 2

In patients with DLBCL

  • Patients with histologically confirmed DLBCL who have failed 2 or more lines of systemic therapy including an anti-CD-20 therapy and an anthracycline or who are not amenable to standard therapies but have an indication for therapy as per investigator's judgement. Standard therapies may also include but are not limited to CAR-T cells therapy, depending on approved therapies in the country where the patient is treated
  • ECOG Performance Status 0, 1 or 2 at the time of screening
  • Measurable disease (radiated lesions do not qualify as target lesions) according to according to RECIL 2017 on the CT scan part of the FDG/PET-CT scan
  • Recovery of therapy-related toxicities from previous anti-lymphoma therapy to CTCAE \<= grade 1 (with the exception of alopecia, peripheral sensory neuropathy grade 2)
  • written informed consent for tumour biopsies (optional)
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

For all patients:

  • Inability to swallow tablets
  • Additional other serious illness, concomitant non-oncological disease (e.g. active infectious disease including an active infection with SARS-CoV-2 confirmed by a PCR test or had one in the prior 6 weeks or active hepatitis (Hep) B infection as defined by positive Hep B DNA test, active Hep C infection as defined by positive Hep C RNA test and human immunodeficiency virus (HIV) infection (positive result in established HIV diagnostic assay), or ongoing toxicity from prior therapies considered by the investigator to potentially compromise patient's safety in this trial
  • Serum creatinine greater than 1.5 mg/dL (>132 µmol/L, SI unit equivalent)
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks or within five times the half-life of the previous investigational drug, whichever is shorter, before start of therapy or concomitant with this trial
  • Patients unable to comply with the protocol
  • Patients who are actively abusing alcohol or drugs. Since no alcohol or drug testing is required per protocol, it is at the investigator's discretion to determine abuse.

For patients with solid tumours:

  • Additional other serious illness , concomitant non-oncological disease (e.g. active infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV), or ongoing toxicity from prior therapies considered by the investigator to potentially compromise patient's safety in this trial
  • History or presence of cardiovascular abnormalities deemed clinically relevant by the investigator such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to study entry.Left Ventricular Ejection Fraction (LVEF) less than 50% at baseline
  • Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the last 28 days before the start of treatment with BI 894999
  • Absolute neutrophil count less than 1500/mm\^3
  • Platelet count less than 100 000/mm\^3
  • Bilirubin greater than 1.5 mg/dL (>26 µmol/L, SI unit equivalent) (except known Gilbert's syndrome, accepted up to 2 mg/dL or up to 34.2 µmol/L in this case)
  • Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases, greater than five times the upper limit of normal)
  • Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks (past two weeks for NC patients) or within five times the half-life of the previous investigational drug, whichever is the shorter, before start of therapy or concomitant with this trial
  • Systemic anti-cancer therapy within four weeks (past two weeks for NC patients) or five times the half-life of the drug, whichever is shorter. Radiotherapy given for curative intent or other than palliative radiotherapy within the past four weeks before start of therapy or concomitantly with this trial. This These restrictions does not apply to LHRH agonists or antagonists, steroids (given at a stable dose in the last four weeks) used for palliative intent, bisphosphonates, and denosumab and to palliative radiotherapy (no wash out required)

For patients with DLBCL:

  • Patient is eligible for curative salvage high dose therapy followed by stem cell transplant.
  • Primary central nervous system (CNS) lymphoma or known CNS involvement
  • Prior allogeneic bone marrow or stem cell transplant
  • High-dose therapy with stem cell support \<3 months prior to visit 1
  • AST or ALT >2.5 x upper limit of normal (CTCAE grade 2 or higher)
  • Total bilirubin >1.5 x upper limit of normal (CTCAE grade 2 or higher)
  • Absolute neutrophil count \<1.0 x 10\^9/L(without growth factor support)
  • Platelets \<100 x 10\^9/L (without transfusions)
  • Significant concurrent medical disease or condition which according to the investigator's judgement would either compromise patient safety or interfere with the evaluation of the safety of the test drug, e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months prior to study entry, cardiac arrhythmia requiring therapy with the exception of extra systoles or minor conduction abnormalities
  • Chronic or ongoing infection requiring treatment at the time of enrolment or within the previous two weeks, e.g. active infectious disease or known Hepatitis B/Hepatitis C infection, HIV
  • Systemic anti-DLBCL therapy within the past two weeks or five times the half-life of the drug, whichever is shorter (palliative radiotherapy and agents used for palliative reasons for example steroids and bisphosphonates, are allowed)
  • Further exclusion criteria apply
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    Phase Ia - Schedule A: 0.2 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule A: 0.5 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule A: 1 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule A: 1.5 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule A: 2 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule A: 5 mg BI 894999

    Once daily continuous oral intake in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 1.5 mg BI 894999

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 2 mg BI 894999

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 2.5 mg BI 894999

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule C: 5/2.5 mg BI 894999

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule C: 6/3 mg BI 894999

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule C: 7/3.5 mg BI 894999

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL patients)

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

  • Experimental
    Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL patients)

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

  • Experimental
    Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ib - Schedule B: 2.5 mg BI 894999 (NC patients)

    Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.

    Drug: BI 894999

  • Experimental
    Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC patients)

    Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.

    Drug: BI 894999

Interventions

  • DrugBI 894999

    film-coated tablets

06

What researchers measure

Primary outcomes

  1. Phase Ia: Number of Patients With DLTs Observed in the First Cycle

    Number of patients with Dose Limiting Toxicities (DLTs) observed in the first treatment cycle of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

    Time frame: First treatment cycle (the first 21 days for Schedules A and B, the first 28 days for Schedule C).

  2. Phase Ib: Number of Patients With DLTs Observed During the On-treatment Period

    Number of patients with Dose Limiting Toxicities (DLTs) observed during the on-treatment period of Phase Ib is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

    Time frame: Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 883 days.

Secondary outcomes

  1. Phase Ia: Number of Patients With DLTs Observed During the On-treatment Period

    Number of patients with DLTs observed during the on-treatment period of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

    Time frame: Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 463 days.

  2. Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)

    Area under the concentration-time curve of BI 894999 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24) for Phase Ia and Phase Ib is reported.

    Time frame: 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1.

  3. Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax)

    Maximum measured concentration of BI 894999 in plasma after the first dose (Cmax) for Phase 1a and Phase 1b is reported.

    Time frame: 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1.

  4. Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss)

    Area under the concentration-time curve of BI 894999 in plasma at steady state over a uniform dosing interval τ (AUCτ, ss) for Phase Ia and Ib is reported. The dosing interval is 24 hours (h) for all dose groups.

    Time frame: 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C).

  5. Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss)

    Maximum measured concentration of BI 894999 in plasma at steady state over a uniform dosing interval τ (Cmax, ss) for Phase Ia and Phase Ib is reported. The dosing interval is 24 hours (h) for all dose groups.

    Time frame: 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C).

  6. Phase Ia and Phase Ib: Objective Response (OR)

    OR was defined as best overall response (BOR) of complete response (CR) or partial response (PR) with tumour assessment during treatment period for each schedule. For DLBCL patients, a minor response according to Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) was not part of an objective response. BOR was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: CT and/ or MRI according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles; * DLBCL patients:FDG-PET/CT scans according to RECIL 2017; every 2 cycles.

    Time frame: Up to 15 months for Phase 1a and up to 28 months for Phase Ib.

  7. Phase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.1

    Progression-free survival (PFS) was defined as the time from date of start of BI 894999 to the date of objective disease progression ((PD) defined as 20% increase in the sum of the longest diameter of target lesions) or death, whichever is earlier for SCLC patients, CRC patients, mCRPC patients with measurable disease by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and NC patients, with tumour assessment every 2 cycles according to RECIST v1.1 during treatment period or Radiological PFS with tumour assessment by bone scan every 4 cycles for mCRPC patients with non-measurable disease by RECIST v1.1. For patients with 'event' as an outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1. For patients with 'censored' as an outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration + 1. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: Up to 28 months.

  8. Phase Ib: Best Overall Response

    Best overall response (BOR) was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: Computerized tomography (CT) and/ or magnetic resonance imaging (MRI) according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles.

    Time frame: Imaging and assessment performed every 2 cycles (solid tumours patients) or 4 cycles (mCRPC patients) for the entire treatment period, up to 28 months.

  9. Phase Ib: Overall Survival

    Overall survival (OS) was defined as the time from first administration of BI 894999 until death from any cause in patients with NUT carcinoma. For patients with 'event' as an outcome for OS: \- OS \[days\] = date of outcome - date of first treatment administration + 1. For patients with 'censored' as an outcome for OS: \- OS (censored) \[days\] = date of outcome - date of first treatment administration + 1. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: Up to 28 months.

  10. Phase Ib: Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

    PSA response was defined as a decline in PSA value ≥50% from baseline (which is confirmed by a second value 3 to 4 weeks apart).

    Time frame: Up to 93 days.

07

Results

Posted Apr 15, 2024
Limitations and caveats
This trial was closed in accordance with protocol-defined criteria for stopping the trial following assessments of futility. Trial was completed as described in protocol.

Participant flow

This was an open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit.

Participant flow — Overall Study
MilestonePhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Started223662661341512842221214112022
Completed0000000000000000000000
Not completed223662661341512842221214112022
Withdrew: Progressive disease223530551131088222191271618
Withdrew: Dose limiting toxicity0000311010010100110200
Withdrew: Other adverse events0001010001320100021221
Withdrew: Refused to continue trial medication0000000000100000001001
Withdrew: Other reasons than listed0000000110110000000022

Outcome measures

PrimaryPhase Ia: Number of Patients With DLTs Observed in the First Cycle

Number of patients with Dose Limiting Toxicities (DLTs) observed in the first treatment cycle of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

Time frame:
First treatment cycle (the first 21 days for Schedules A and B, the first 28 days for Schedule C).
Reported as:
Count of participants · Participants
Phase Ia: Number of Patients With DLTs Observed in the First Cycle
ParticipantsPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)
Phase Ia: Number of Patients With DLTs Observed in the First Cycle00003210202411200
PrimaryPhase Ib: Number of Patients With DLTs Observed During the On-treatment Period

Number of patients with Dose Limiting Toxicities (DLTs) observed during the on-treatment period of Phase Ib is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

Time frame:
Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 883 days.
Reported as:
Count of participants · Participants
Phase Ib: Number of Patients With DLTs Observed During the On-treatment Period
ParticipantsPhase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Phase Ib: Number of Patients With DLTs Observed During the On-treatment Period32723
SecondaryPhase Ia: Number of Patients With DLTs Observed During the On-treatment Period

Number of patients with DLTs observed during the on-treatment period of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule.

Time frame:
Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 463 days.
Reported as:
Count of participants · Participants
Phase Ia: Number of Patients With DLTs Observed During the On-treatment Period
ParticipantsPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)
Phase Ia: Number of Patients With DLTs Observed During the On-treatment Period00024210313412212
SecondaryPhase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)

Area under the concentration-time curve of BI 894999 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24) for Phase Ia and Phase Ib is reported.

Time frame:
5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1.
Reported as:
Geometric mean · nanomole * hour /Liter (nmol*h/L)
Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)
nanomole * hour /Liter (nmol*h/L)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)Phase Ib - Schedule B: BI 894999 2 mg (Solid Tumours Including NC)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule B: BI 894999 2.5 mg (Solid Tumours Including NC)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)
Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)4.36 ± 21.16.43 ± 2.7820.5 ± 16.834.0 ± 69.464.9 ± 71.0—27.7 ± 81.544.8 ± 34.851.5 ± 41.7123 ± 37.6212 ± 45.5230 ± 27.331.7 ± 33.448.0 ± 26.953.3 ± 6.91138 ± 7.52—NA ± NA39.2 ± 38.856.9 ± 58.667.6 ± 50.9214 ± 6.01
SecondaryPhase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax)

Maximum measured concentration of BI 894999 in plasma after the first dose (Cmax) for Phase 1a and Phase 1b is reported.

Time frame:
5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1.
Reported as:
Geometric mean · nanomole/L (nmol/L)
Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax)
nanomole/L (nmol/L)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)Phase Ib - Schedule B: BI 894999 2 mg (Solid Tumours Including NC)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule B: BI 894999 2.5 mg (Solid Tumours Including NC)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)
Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax)0.393 ± 35.60.569 ± 46.21.75 ± 31.63.79 ± 84.07.39 ± 56.016.2 ± 68.03.00 ± 1553.93 ± 50.24.48 ± 46.612.0 ± 85.119.4 ± 58.421.0 ± 48.32.98 ± 34.94.49 ± 36.04.75 ± 0.59513.9 ± 12.8NA ± NANA ± NA4.10 ± 37.84.88 ± 50.16.01 ± 59.618.8 ± 55.8
SecondaryPhase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss)

Area under the concentration-time curve of BI 894999 in plasma at steady state over a uniform dosing interval τ (AUCτ, ss) for Phase Ia and Ib is reported. The dosing interval is 24 hours (h) for all dose groups.

Time frame:
5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C).
Reported as:
Geometric mean · nanomole *hour/Liter (nmol*h/)L
Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss)
nanomole *hour/Liter (nmol*h/)LPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (NC Patients Only)Phase Ib - Schedule B: BI 894999 2 mg (Solid Tumours Including NC)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule B: BI 894999 2.5 mg (Solid Tumours Including NC)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)
Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss)10.3 ± 72.617.9 ± 46.454.6 ± 40.476.4 ± 26.6119 ± 90.3NA ± NA62.6 ± 49.281.1 ± 32.187.0 ± 28.3144 ± 46.4176 ± 37.0226 ± 63.270.3 ± 38.5120 ± 19.6NA ± NANA ± NANA ± NA—NA ± NA73.6 ± 58.294.9 ± 43.9125 ± 50.4149 ± 56.7
SecondaryPhase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss)

Maximum measured concentration of BI 894999 in plasma at steady state over a uniform dosing interval τ (Cmax, ss) for Phase Ia and Phase Ib is reported. The dosing interval is 24 hours (h) for all dose groups.

Time frame:
5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C).
Reported as:
Geometric mean · nanomole/Liter (nmol/L)
Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss)
nanomole/Liter (nmol/L)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (NC Patients Only)Phase Ib - Schedule B: BI 894999 2 mg (Solid Tumours Including NC)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule B: BI 894999 2.5 mg (Solid Tumours Including NC)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)
Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss)0.697 ± 59.81.26 ± 24.94.06 ± 61.75.25 ± 60.111.6 ± 54.4NA ± NA4.75 ± 46.95.62 ± 27.76.94 ± 42.011.4 ± 56.113.1 ± 41.817.1 ± 63.65.48 ± 32.77.67 ± 8.44NA ± NANA ± NANA ± NA—NA ± NA6.51 ± 70.07.68 ± 45.410.4 ± 59.411.2 ± 60.1
SecondaryPhase Ia and Phase Ib: Objective Response (OR)

OR was defined as best overall response (BOR) of complete response (CR) or partial response (PR) with tumour assessment during treatment period for each schedule. For DLBCL patients, a minor response according to Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) was not part of an objective response. BOR was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: CT and/ or MRI according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles; * DLBCL patients:FDG-PET/CT scans according to RECIL 2017; every 2 cycles.

Time frame:
Up to 15 months for Phase 1a and up to 28 months for Phase Ib.
Reported as:
Count of participants · Participants
Phase Ia and Phase Ib: Objective Response (OR)
ParticipantsPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Phase Ia and Phase Ib: Objective Response (OR)0101001000000100000112
SecondaryPhase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.1

Progression-free survival (PFS) was defined as the time from date of start of BI 894999 to the date of objective disease progression ((PD) defined as 20% increase in the sum of the longest diameter of target lesions) or death, whichever is earlier for SCLC patients, CRC patients, mCRPC patients with measurable disease by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and NC patients, with tumour assessment every 2 cycles according to RECIST v1.1 during treatment period or Radiological PFS with tumour assessment by bone scan every 4 cycles for mCRPC patients with non-measurable disease by RECIST v1.1. For patients with 'event' as an outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1. For patients with 'censored' as an outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration + 1. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
Up to 28 months.
Reported as:
Median · Weeks
Phase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.1
WeeksPhase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Phase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.15.6 (5.3 to 6.1)5.6 (4.4 to 10.7)11.9 (8.1 to 24.4)6.9 (6.0 to 11.1)7.8 (4.0 to 13.0)
SecondaryPhase Ib: Best Overall Response

Best overall response (BOR) was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: Computerized tomography (CT) and/ or magnetic resonance imaging (MRI) according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles.

Time frame:
Imaging and assessment performed every 2 cycles (solid tumours patients) or 4 cycles (mCRPC patients) for the entire treatment period, up to 28 months.
Reported as:
Count of participants · Participants
Phase Ib: Best Overall Response
ParticipantsPhase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Complete response00001
Partial response00111
Stable disease12276
Progressive disease810499
Not evaluable32435
Not assessed00000
SecondaryPhase Ib: Overall Survival

Overall survival (OS) was defined as the time from first administration of BI 894999 until death from any cause in patients with NUT carcinoma. For patients with 'event' as an outcome for OS: \- OS \[days\] = date of outcome - date of first treatment administration + 1. For patients with 'censored' as an outcome for OS: \- OS (censored) \[days\] = date of outcome - date of first treatment administration + 1. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
Up to 28 months.
Reported as:
Median · Weeks
Phase Ib: Overall Survival
WeeksPhase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)
Phase Ib: Overall Survival6.6 (NA to NA)15.4 (7.6 to 32.3)
SecondaryPhase Ib: Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

PSA response was defined as a decline in PSA value ≥50% from baseline (which is confirmed by a second value 3 to 4 weeks apart).

Time frame:
Up to 93 days.
Reported as:
Count of participants · Participants
Phase Ib: Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
ParticipantsPhase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)
Phase Ib: Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)0

Adverse events

Collected over [All-Cause Mortality]: From first date of dosing until end of study, up to 1309 days for Phase Ia and up to 860 days for Phase Ib. [Serious and Other Adverse Events]: From first date of dosing of study treatment until date of the last dosing of study treatment + 30 days residual effect period, up to 463 days for Phase 1a and up to 883 days for Phase Ib.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase Ia - Schedule A: 0.2 mg BI 8949990/2 (0%)1/2 (50%)2/2 (100%)
Phase Ia - Schedule A: 0.5 mg BI 8949990/2 (0%)2/2 (100%)2/2 (100%)
Phase Ia - Schedule A: 1 mg BI 8949990/3 (0%)0/3 (0%)3/3 (100%)
Phase Ia - Schedule A: 1.5 mg BI 8949991/6 (16.7%)3/6 (50%)6/6 (100%)
Phase Ia - Schedule A: 2 mg BI 8949991/6 (16.7%)2/6 (33.3%)6/6 (100%)
Phase Ia - Schedule A: 5 mg BI 8949990/2 (0%)1/2 (50%)2/2 (100%)
Phase Ia - Schedule B: 1.5 mg BI 8949991/6 (16.7%)3/6 (50%)6/6 (100%)
Phase Ia - Schedule B: 2 mg BI 8949991/6 (16.7%)3/6 (50%)6/6 (100%)
Phase Ia - Schedule B: 2.5 mg BI 8949992/13 (15.4%)6/13 (46.2%)12/13 (92.3%)
Phase Ia - Schedule C: 5/2.5 mg BI 8949990/4 (0%)2/4 (50%)4/4 (100%)
Phase Ia - Schedule C: 6/3 mg BI 8949992/15 (13.3%)8/15 (53.3%)15/15 (100%)
Phase Ia - Schedule C: 7/3.5 mg BI 8949991/12 (8.3%)8/12 (66.7%)12/12 (100%)
Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)0/8 (0%)3/8 (37.5%)8/8 (100%)
Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)0/4 (0%)2/4 (50%)4/4 (100%)
Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)0/2 (0%)2/2 (100%)2/2 (100%)
Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients1/2 (50%)1/2 (50%)2/2 (100%)
Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)0/2 (0%)0/2 (0%)2/2 (100%)
Phase Ib - Schedule B: 2.5 mg BI 894999 (SCLC Patients)0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase Ib - Schedule B: 2 mg BI 894999 (SCLC Patients)1/9 (11.1%)3/9 (33.3%)9/9 (100%)
Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)0/14 (0%)8/14 (57.1%)14/14 (100%)
Phase Ib - Schedule B: 2.5 mg BI 894999 (mCRPC Patients)0/10 (0%)8/10 (80%)10/10 (100%)
Phase Ib - Schedule B: 2 mg BI 894999 (mCRPC Patients)0/1 (0%)1/1 (100%)1/1 (100%)
Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)5/20 (25%)15/20 (75%)20/20 (100%)
Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)2/21 (9.5%)12/21 (57.1%)21/21 (100%)
Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL PatientsPhase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)
FatigueGeneral disorders0/20/20/30/60/60/20/60/60/130/40/151/120/80/40/20/20/20/30/90/140/100/11/201/211/1
Platelet count decreasedInvestigations0/20/20/30/60/60/20/60/60/130/40/150/120/80/40/20/20/20/30/90/140/101/12/200/211/1
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders0/20/20/30/60/60/20/60/60/130/40/150/120/80/40/20/20/20/30/90/140/100/11/200/211/1
ThrombocytopeniaBlood and lymphatic system disorders0/20/20/30/60/60/20/60/60/130/40/151/120/80/40/20/20/22/30/90/140/100/12/201/210/1
Febrile neutropeniaBlood and lymphatic system disorders0/20/20/30/60/60/20/60/60/130/40/150/120/80/41/20/20/20/30/90/140/100/10/200/210/1
AstheniaGeneral disorders0/21/20/30/60/60/20/60/60/130/40/150/120/80/40/20/20/20/30/90/140/100/10/200/210/1
General physical health deteriorationGeneral disorders0/20/20/30/60/60/20/60/60/130/40/151/120/80/40/21/20/20/30/90/140/100/10/200/210/1
PyrexiaGeneral disorders0/20/20/30/60/61/20/60/60/130/40/150/120/80/41/20/20/20/30/90/141/100/10/200/210/1
SepsisInfections and infestations0/20/20/30/60/60/21/60/60/130/40/150/120/80/41/20/20/20/30/90/140/100/11/200/210/1
DehydrationMetabolism and nutrition disorders0/20/20/30/60/61/20/60/60/130/40/150/120/80/40/20/20/20/30/91/140/100/10/200/210/1
Most frequent other events
Showing 10 of 268
Most frequent other events
EventPhase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL PatientsPhase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: BI 894999 6/3 mg (NC Patients)Phase Ib - Schedule C: BI 894999 7/3.5 mg (NC Patients)
AnaemiaBlood and lymphatic system disorders0/21/20/31/61/60/22/62/64/130/45/156/121/80/41/21/21/21/30/93/149/101/111/206/210/1
NeutropeniaBlood and lymphatic system disorders0/20/20/30/62/61/20/60/63/130/40/151/123/82/40/20/22/20/31/90/141/100/12/200/210/1
ThrombocytopeniaBlood and lymphatic system disorders0/20/21/32/65/61/20/63/66/132/48/157/124/84/42/20/21/22/32/95/145/100/15/205/210/1
Atrial fibrillationCardiac disorders0/20/20/30/60/60/20/60/61/130/40/150/120/80/40/20/20/20/30/90/140/100/11/200/211/1
Vitreous haemorrhageEye disorders0/20/20/30/60/60/20/60/60/130/40/150/120/80/40/20/20/20/30/90/140/101/10/200/210/1
Abdominal painGastrointestinal disorders0/20/20/31/61/61/20/60/60/130/41/151/121/81/40/20/20/20/31/93/140/100/11/204/211/1
DiarrhoeaGastrointestinal disorders0/21/20/31/60/62/23/62/66/133/48/153/122/83/42/22/22/20/33/98/146/100/14/209/210/1
DysphagiaGastrointestinal disorders0/20/20/30/60/60/20/61/60/130/41/150/120/80/40/20/20/21/31/90/140/100/12/200/211/1
StomatitisGastrointestinal disorders0/20/20/32/60/62/21/61/60/131/40/150/120/80/40/20/20/21/30/90/141/101/10/202/210/1
FatigueGeneral disorders2/21/23/34/64/62/21/63/66/132/48/1510/120/83/41/21/20/21/33/96/146/100/18/2010/210/1

Baseline characteristics

For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg . For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg.

Age, Continuous
Age, Continuous(Years)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)Total
Mean63.5 ± 10.669.5 ± 2.146.7 ± 9.357.5 ± 11.953.5 ± 18.154.5 ± 26.260.7 ± 10.861.5 ± 13.064.5 ± 7.563.3 ± 12.859.7 ± 12.062.5 ± 6.571.4 ± 10.978.8 ± 9.068.5 ± 2.168.5 ± 2.179.0 ± 9.963.5 ± 7.366.2 ± 6.369.7 ± 4.144.4 ± 13.940.5 ± 16.558.6 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)Total
Female102260314257111015605861
Male12140235921057312178111514113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)Total
Hispanic or Latino00001000001200000010016
Not Hispanic or Latino223652661341410242218891717143
Unknown or Not Reported000000000000600014523425
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase Ia - Schedule A: 0.2 mg BI 894999Phase Ia - Schedule A: 0.5 mg BI 894999Phase Ia - Schedule A: 1 mg BI 894999Phase Ia - Schedule A: 1.5 mg BI 894999Phase Ia - Schedule A: 2 mg BI 894999Phase Ia - Schedule A: 5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999Phase Ia - Schedule B: 2 mg BI 894999Phase Ia - Schedule B: 2.5 mg BI 894999Phase Ia - Schedule C: 5/2.5 mg BI 894999Phase Ia - Schedule C: 6/3 mg BI 894999Phase Ia - Schedule C: 7/3.5 mg BI 894999Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL Patients)Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC Patients)Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC Patients)Phase Ib - Schedule B: 2.5 mg BI 894999 (NC Patients)Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC Patients)Total
American Indian or Alaska Native00000000000000000000000
Asian00000000000000000000314
Native Hawaiian or Other Pacific Islander00000000000000000000000
Black or African American00000000000000000101013
White223662661341512242107981416140
More than one race00000000000000000000000
Unknown or Not Reported000000000000600124523427
08

Study locations

16 sites
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Brussels - HOSP Jules Bordet
    Anderlecht, 1070, Belgium
  • Brussels - UNIV Saint-Luc
    Brussels, 1200, Belgium
  • UNIV UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • HOP Timone
    Marseille, 13385, France
  • HOP Hôtel-Dieu
    Nantes, 44000, France
  • HOP Saint-Louis
    Paris, 75475, France
  • INS Gustave Roussy
    Villejuif, 94800, France
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Publications

  • Schoffski P, Machiels JP, Rottey S, Sadrolhefazi B, Musa H, Marzin K, Awada A. Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. Eur J Cancer. 2023 Sep;191:112987. doi: 10.1016/j.ejca.2023.112987. Epub 2023 Jul 11. PubMed 37556913 ↗

Related links

Study documents

  • Study protocol · Jun 24, 2020
  • Statistical analysis plan · Jan 19, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02516553
Lead sponsor
Boehringer Ingelheim
Responsible party
Sponsor
First posted
Aug 6, 2015
Start date
Jul 8, 2015
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Results posted
Apr 15, 2024
Last update
Apr 15, 2024

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms →

Other studies from this sponsor

Boehringer Ingelheim →

Start the discussion